Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
Sign Up to like & getrecommendations! Published in 2020 at "Leukemia"
DOI: 10.1038/s41375-020-0758-4
Abstract: Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either… read more here.
Keywords: atra ctx; ctx; ato atra; outcome older ... See more keywords
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Blood Cancer Journal"
DOI: 10.1038/s41408-022-00619-3
Abstract: Dear Editor, Multiple studies have established the synergy between ATO and ATRA in APL, and a combination of these drugs without chemotherapy is the new standard of care in low and intermediate-risk patients [1–5]. Post… read more here.
Keywords: risk; analysis; combination; induction ... See more keywords